Recurrent Squamous Cell Carcinoma
Oncology
0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
Alpha Tau MedicalDaRT seeds
Clinical Trials (1)
Total enrollment: 86 patients across 1 trials
A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma
Start: Sep 2022Est. completion: Dec 202586 patients
N/ARecruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
24m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
24m ago
Office Administrator
SystImmune
24m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
34m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
38m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
38m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 86 patients
1 companies competing in this space